Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 bridging study of luspatercept for transfusion-dependent anemia in lower-risk MDS with ring sideroblasts
jRCT2080225292Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2020
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
01
Overview
Phase 2, open-label, single-arm trial of luspatercept in myelodysplastic syndrome (MDS), sponsored by Bristol Myers Squibb. Primary endpoint: Efficacy of luspatercept. Started Jul 2020; status: completed.
02
Drugs
luspatercept
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on jRCT2080225292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225292.